

MarketRising

Top 5 Stocks that Could Double in 2025

Over the last two years – in 2023 and 2024 – the S&P 500 was up more than 50%, providing investors with a wealth of opportunities to pocket significant gains.

2025 is shaping up to be another year filled with outstanding opportunities and a number of high-growth stocks now present the potential to double in value in the months ahead.

This year looks to offer such outstanding potential for a number of reasons, including the technological advancements brought about by the artificial intelligence (AI) boom... the ushering in of more business-friendly policies in the energy industry by the Trump administration...and continued advances in healthcare and biotech.

While there are obviously no guarantees when it comes to investing, what follows is a list of high-growth stocks – in particularly attractive sectors – that offer significant upside for the months ahead.

Each of the carefully-selected stocks below could provide the potential to double or more in 2025 under the right circumstances.

As always, please be sure to do your own due diligence and research any potential investment carefully before making any investment decision.

“Doubler” Stock #1 – Novo Nordisk A/S (NYSE: NVO)



Novo Nordisk A/S (NYSE: NVO), together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

Over the past year, shares of the stock have fallen by roughly 30% but there is significant upside potential ahead for this company.

That's because the company focuses on diabetes and weight loss, which are two of the fastest-growing areas of focus within the healthcare industry.

The company's products include Ozempic and Wegovy, which focus on diabetes and weight loss respectively and it has an impressive pipeline of future drug candidates. Novo Nordisk is a leader in the lucrative GLP-1 market, serving nearly two-thirds of all patients on GLP-1 treatments.

On February 5, 2025 the company released its Q4 2024 earnings, which included a 26% increase in sales growth...a 57% increase in obesity care sales growth...an increase in gross margin from 84.6% in 2023 to 84.7% in 2024.

"Doubler" Stock #2 – Matador Resources Company (NYSE: MTDR)



Matador Resources Company (NYSE: MTDR) is an independent energy company, engages in the exploration, development, production, and acquisition of oil and natural gas resources in the United States.

The company is especially attractive at current prices as it has grown its revenue at a compound annual growth rate of 29% over the past five years.

Additionally, the company is targeting significantly accelerated production in 2025 with a target of 200,000 barrels of oil equivalent per day in the hopes of taking advantage of oil price funding support above the \$70-per-barrel level.

The company primarily holds interests in the Wolfcamp and Bone Spring plays in the Delaware Basin in Southeast New Mexico and West Texas. It also operates the Eagle Ford shale play in South Texas; and the Haynesville shale and Cotton Valley plays in Northwest Louisiana.

In addition, the company conducts midstream operations in support of its exploration, development, and production operations. Further, it provides natural gas processing and oil transportation services; and oil, natural gas, and produced water gathering services, as well as produced water disposal services to third parties.

“Doubler” Stock #3 – Legend Biotech Corporation (Nasdaq: LEGN)



Legend Biotech Corporation (Nasdaq: LEGN) is a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.

The company's lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). Legend Biotech Corp. also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.

Legend Biotech Corp. is well-positioned to capitalize on advancements in multiple myeloma treatments, evidenced by the promising Phase 3 CARTITUDE-4 study results showing significant MRD-negativity rates.

This positions the company's leading drug – CARVYKTI® – as a pivotal therapy in earlier treatment lines, potentially reshaping patient outcomes and bolstering Legend's market stance

In the company's reporting of its Q3 2024 results, CARVYKTI® was reported to have generated net trade sales worth \$286 million, representing operational growth of 87.6% year-over-year, and 53.2% sequentially.

"Doubler" Stock #4 – Advanced Micro Devices, Inc. (Nasdaq: AMD)



Advanced Micro Devices, Inc. (Nasdaq: AMD) is a semiconductor company operating in the global market. It operates through Data Center, Client, Gaming, and Embedded segments.

The company designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications.

Traditionally, the company's strength has been in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox.

In early January 2025, analyst Gus Richard with Northland Capital Markets named AMD as one of his Top Picks for 2025 and estimated the company's AI revenue will reach \$9.5 billion in 2025, up from \$5.2 billion last year.

Richard said, "We expect AMD to continue to gain share in AI GPUs, server CPUs, and PC clients as headwinds from the embedded and gaming segments abate. AMD is winning share in AI based on its roadmap and TCO. AMD has better products for server and client CPUs. The PC refresh cycle will likely be much stronger than currently expected. We think there is significantly more upside to CY 2025 than risks."

"Doubler" Stock #5 – Vericel Corporation (Nasdaq: VCEL)



Vericel Corporation (Nasdaq: VCEL) is a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.

The company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives.

Vericel markets three products in the United States: (1) MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. (2) Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. (3) Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns.

The company recently reported total net revenue growth of roughly 20% for the full year 2024 and stated that gross margin is expected to be 72.5%. Total net revenue growth for 2025 is projected to be 20% to 23% with gross margins between 73% to 74%.